摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-羟基-4,4-二甲基己烷-1,2-二基二硝酸酯 | 1034454-12-0

中文名称
6-羟基-4,4-二甲基己烷-1,2-二基二硝酸酯
中文别名
——
英文名称
6-hydroxy-4,4-dimethylhexane-1,2-diyl dinitrate
英文别名
(6-hydroxy-4,4-dimethyl-1-nitrooxyhexan-2-yl) nitrate
6-羟基-4,4-二甲基己烷-1,2-二基二硝酸酯化学式
CAS
1034454-12-0
化学式
C8H16N2O7
mdl
——
分子量
252.224
InChiKey
PAJXKWOLMFXETC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    17
  • 可旋转键数:
    7
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    130
  • 氢给体数:
    1
  • 氢受体数:
    7

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] NITRIC OXIDE DONOR COMPOUNDS<br/>[FR] COMPOSÉS DONNEURS D'OXYDE NITRIQUE
    申请人:NICOX SA
    公开号:WO2009098113A1
    公开(公告)日:2009-08-13
    The invention relates to nitric oxide donors of the formula (I) and pharmaceutically acceptable salts or stereoisomers thereof : wherein A and A' are independently selected from the group consisting of H and -(X)s-Y with the proviso that at least one of A or A' is not H; wherein s is 0 or 1; X is selected from the group consisting of : -CO-, -COO-, -CONH- and -SO2- or (A); Y is straight or branched C1-C20 alkyl chain, preferably C1- C10 alkyl chain, substituted with one or two -ONO2; or C1-C6 alkylenoxy- C1-C5 alkyl wherein the alkyl group is substituted by one or two -ONO2 groups. The invention also provides novel compositions comprising at least one compound of the invention and at least one therapeutic agent.
    该发明涉及化学式(I)的一氧化氮供体及其药用盐或立体异构体:其中A和A'分别选自H和-(X)s-Y组成的组,但至少其中之一不是H;其中s为0或1;X选自以下组成的组:-CO-,-COO-,-CONH-和-SO2-或(A);Y是直链或支链的C1-C20烷基链,优选C1-C10烷基链,取代有一个或两个-ONO2基团;或C1-C6烷氧基-C1-C5烷基,其中烷基基团取代有一个或两个-ONO2基团。该发明还提供了包括至少一种该发明化合物和至少一种治疗剂的新型组合物。
  • Angiotensin II receptor antagonists
    申请人:Sebhat Iyassu K.
    公开号:US20080194660A1
    公开(公告)日:2008-08-14
    A compound having the structure wherein R is an angiotensin receptor antagonist active group, Y is -Y 1 -Y 2 -Y 3 -Y 4 -Y 5 -; Y 1 is C(R 1 R 2 ); R 1 is selected from the group consisting of hydrogen and C 1-4 alkyl; R 2 is selected from the group consisting of hydrogen, C 1-4 alkyl, and —OC(O)C 1-4 alkyl; Y 2 is O or CH 2 ; Y 3 is C(O) or CH 2 ; Y 4 is O or CH 2 ; Y 5 is —(CH 2 ) 1-2 —(X) 0-1 —(CH 2 ) 0-1 — or is absent; X is —O— or —CR 3 R 4 —; and R 3 and R 4 are independently selected from the group consisting of hydrogen and C 1 -C 4 alkyl; or a pharmaceutically acceptable salt or hydrate thereof, which is useful for treating hypertension.
    一种具有以下结构的化合物,其中R是一种血管紧张素受体拮抗剂活性基团,Y为-Y1-Y2-Y3-Y4-Y5-;Y1为C(R1R2);R1选择自氢和C1-4烷基组成的群;R2选择自氢、C1-4烷基和—OC(O)C1-4烷基组成的群;Y2为O或CH2;Y3为C(O)或CH2;Y4为O或CH2;Y5为—(CH2)1-2—(X)0-1—(CH2)0-1—或不存在;X为—O—或—CR3R4—;R3和R4独立选择自氢和C1-C4烷基组成的群;或其药学上可接受的盐或水合物,适用于治疗高血压。
  • Nitric oxide donor compounds
    申请人:Nicox S.A.
    公开号:US08003811B2
    公开(公告)日:2011-08-23
    The invention relates to nitric oxide donors of the formula (I) and pharmaceutically acceptable salts or stereoisomers thereof: wherein A and A′ are independently selected from the group consisting of H and —(X)s—Y with the proviso that at least one of A or A′ is not H; wherein s is 0 or 1; X is selected from the group consisting of: —CO—, —COO—, —CONH— and —SO2— or Y is straight or branched C1-C20 alkyl chain, preferably C1-C10 alkyl chain, substituted with one or two —ONO2; or C1-C6 alkylenoxy-C1-C5 alkyl wherein the alkyl group is substituted by one or two —ONO2 groups. The invention also provides novel compositions comprising at least one compound of the invention and at least one therapeutic agent.
    本发明涉及公式(I)的一氧化氮供体及其药学上可接受的盐或立体异构体:其中A和A′独立地选自H和—(X)s—Y所组成的群,但至少其中之一不是H;其中s为0或1;X选自以下群:—CO—,—COO—,—CONH—和—SO2—或Y为直链或支链的C1-C20烷基链,优选为C1-C10烷基链,其上取代有一或两个—ONO2;或C1-C6烷氧基-C1-C5烷基,其中烷基上取代有一或两个—ONO2基团。本发明还提供了包含本发明中至少一种化合物和至少一种治疗剂的新型组合物。
  • NITRIC OXIDE DONOR COMPOUNDS
    申请人:Almirante Nicoletta
    公开号:US20100249189A1
    公开(公告)日:2010-09-30
    The invention relates to nitric oxide donors of the formula (I) and pharmaceutically acceptable salts or stereoisomers thereof: wherein A and A′ are independently selected from the group consisting of H and —(X) S —Y with the proviso that at least one of A or A′ is not H; wherein s is 0 or 1; X is selected from the group consisting of: —CO—, —COO—, —CONH— and —SO 2 — or Y is straight or branched C 1 -C 20 alkyl chain, preferably C 1 -C 10 alkyl chain, substituted with one or two —ONO 2 ; or C 1 -C 6 alkylenoxy-C 1 -C 5 alkyl wherein the alkyl group is substituted by one or two —ONO 2 groups. The invention also provides novel compositions comprising at least one compound of the invention and at least one therapeutic agent.
    本发明涉及公式(I)的一氧化氮供体及其药学上可接受的盐或立体异构体:其中A和A'分别独立地选自H和—(X)S—Y组成的群,但其中至少一个不是H;其中s为0或1;X选自以下组成的群:—CO—、—COO—、—CONH—和—SO2—,或Y是直链或支链的C1-C20烷基链,优选C1-C10烷基链,其中一个或两个—ONO2取代,或者是C1-C6烷氧基-C1-C5烷基,其中烷基取代一个或两个—ONO2基团。本发明还提供了包含本发明中至少一种化合物和至少一种治疗剂的新型组合物。
  • [EN] STATIN DERIVATES AND INTERMEDIATES FOR THEIR PRODUCTION<br/>[FR] DÉRIVÉS DE STATINES
    申请人:NICOX SA
    公开号:WO2011160974A3
    公开(公告)日:2012-04-05
查看更多